Meilan M. Rutter

Meilan M. Rutter

Auto-generated profile, based on publicly available information

Meilan M. Rutter

Cincinnati Children’s Hospital Medical Center

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MRMeilan M. Rutter
Meilan M. Rutter
PJPranati Jha
Pranati Jha
KSKris Ann P. Schultz
Kris Ann P. Schultz
ASAmy Sheil
Amy Sheil
AHAnne K. Harris
Anne K. Harris
DHD. Ashley Hill
D. Ashley Hill
Context: DICER1 germline mutation carriers have an increased predisposition to cancer, such as pleuropulmonary blastoma (PPB) and Sertoli-Leydig cell tumor (SLCT), and a high prevalence of multinodular goiter (MNG). Although differentiated thyroid carcinoma (DTC) has been reported in some DICER1 mutation carriers with PPB treated with chemotherapy, the association of DTC with DICER1 mutations is not well established. Case Description: We report a family with DICER1 mutation and familial DTC without a history of chemotherapy. A 12-year-old female (patient A) and her 14-year-old sister (patient B) presented with MNG. Family history was notable for a maternal history of DTC and bilateral ovarian SLCT. Both sisters underwent total thyroidectomy. Pathological examination showed nodular hyperplasia and focal papillary thyroid carcinoma within hyperplastic nodules. Subsequently, patient A developed virilization secondary to a unilateral ovarian SLCT. During her evaluation, an incidental cystic nephroma was also found. Three other siblings had MNG on surveillance ultrasound examination; two had thyroidectomies, and one had two microscopic foci of papillary carcinoma. Patient A, her mother, and four affected siblings had a germline heterozygous pathogenic DICER1 mutation c.5441C>T in exon 25, resulting in an amino acid change from p.Ser1814Leu of DICER1. Somatic DICER1 RNase IIIb missense mutations were identified in thyroid nodules from three of the four siblings. Conclusions: This family provides novel insight into an emerging phenotype for DICER1 syndrome, with evidence that germline DICER1 mutations are associated with an increased risk of developing familial DTC, even in the absence of prior treatment with chemotherapy.

1 November 2016 in Neuromuscular Disorders
Verified
Journal Article
Closed access
CTCuixia Tian
Cuixia Tian
BWBrenda L. Wong
Brenda L. Wong
LHLindsey Hornung
Lindsey Hornung
JKJane C. Khoury
Jane C. Khoury
LMLauren Miller
Lauren Miller
MRMeilan M. Rutter
Meilan M. Rutter

1 December 2012 in Neuromuscular Disorders
Verified
Journal Article
Closed access
MRMeilan M. Rutter
Meilan M. Rutter
JCJames Collins
James Collins
SRSusan R. Rose
Susan R. Rose
JWJessica G. Woo
Jessica G. Woo
HSHeidi Sucharew
Heidi Sucharew
BWBrenda L. Wong
Brenda L. Wong

12 September 2013 in International Journal of Pediatric Endocrinology
Verified
Journal Article
Open access
PDF file
JCJanet Chuang
Janet Chuang
AVAmy Vallerie
Amy Vallerie
LBLesley Breech
Lesley Breech
HSHoward M Saal
Howard M Saal
SAShumyle Alam
Shumyle Alam
MRMeilan M Rutter
Meilan M Rutter
Background: 17β-Hydroxysteroid dehydrogenase type-3 (17βHSD-3) deficiency is a rare cause of 46,XY disorders of sex development. The enzyme converts androstenedione to testosterone, necessary for masculinization of male genitalia in utero. 17βHSD-3 deficiency is frequently diagnosed late, at puberty, following virilization, with consequent female-to-male gender reassignment in 39-64%. The decision for sex of rearing is difficult, especially if diagnosed in early childhood. Consensus guidelines are equivocal or support male gender assignment. Long-term outcomes data to guide decisions are also lacking; however, in the few cases of early diagnosis and orchiectomy, female gender retention appears more likely. We report two patients with 17βHSD-3 deficiency, who presented at unusual ages, in whom female gender was chosen. We performed a focused literature review and summary of gender outcomes in 17βHSD-3 deficiency following early orchiectomy. Cases: Patient A was a phenotypic female who presented at one year of age with bilateral inguinal hernias and external female genitalia. Testes were identified at surgery. The karyotype was 46,XY. She was initially diagnosed with complete androgen insensitivity syndrome; however, androgen receptor mutation analysis was negative. Human chorionic gonadotropin stimulation yielded a low testosterone: androstenedione ratio (0.6, normal >0.8). Genetic testing demonstrated compound heterozygosity for two known mutations of the HSD17B3 gene. She underwent bilateral orchiectomy at two years of age. Patient B was born with female genitalia and virilized at 13 years of age. She did not seek evaluation until 22 years of age. Her karyotype was 46,XY. She had bilateral inguinal testes and low testosterone: androstenedione ratio (0.3). HSD17B3 gene sequencing showed her to be a compound heterozygote for two known mutations. She identified herself as female and underwent bilateral orchiectomy and estrogen replacement therapy. Conclusions: These two patients highlight the complexities of diagnosis and management in 17βHSD-3 deficiency. Although existing data are limited, early orchiectomy is likely to result in retention of female gender identity, avoiding the complications related to virilization in adolescence. As such, it is important to pursue a definitive diagnosis to guide clinical decisions, and to have the support and long term follow up with an inter-disciplinary disorders of sex development team.

Verified
Journal Article
Open access
Phyllis W. SpeiserPhyllis W. Speiser
Phyllis W. Speiser
RCReeti Chawla
Reeti Chawla
MCMing Chen
Ming Chen
ADAlicia Diaz-Thomas
Alicia Diaz-Thomas
CFCourtney Finlayson
Courtney Finlayson
EDEmmanuèle Délot
Emmanuèle Délot
Newborn screening for congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency is mandated throughout the US. Filter paper blood specimens are assayed for 17-hydroxyprogesterone (17OHP). Prematurity, low birth weight, or critical illness cause falsely elevated results. The purpose of this report is to highlight differences in protocols among US state laboratories. We circulated a survey to state laboratory directors requesting qualitative and quantitative information about individual screening programs. Qualitative and quantitative information provided by 17 state programs were available for analysis. Disease prevalence ranged from 1:9941 to 1:28,661 live births. Four state laboratories mandated a second screen regardless of the initial screening results; most others did so for infants in intensive care units. All but one program utilized birthweight cut-points, but cutoffs varied widely: 17OHP values of 25 to 75 ng/mL for birthweights >2250–2500 g. The positive predictive values for normal birthweight infants varied from 0.7% to 50%, with the highest predictive values based in two of the states with a mandatory second screen. Data were unavailable for negative predictive values. These data imply differences in sensitivity and specificity in CAH screening in the US. Standardization of newborn screening protocols could improve the positive predictive value.

28 February 2020 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
MRMeilan M. Rutter
Meilan M. Rutter
BWBrenda L. Wong
Brenda L. Wong
JCJames J. Collins
James J. Collins
HSHemant Sawnani
Hemant Sawnani
MTMichael D. Taylor
Michael D. Taylor
PBPhilippe F. Backeljauw
Philippe F. Backeljauw